* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRAX vs IBRX, CORT, KYMR: Buyback Yield % Comparison
For the Biotechnology subindustry, Praxis Precision Medicines's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Praxis Precision Medicines (PRAX) has a Buyback Yield % of -14.13 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Praxis Precision Medicines and its competitors. According to the industry distribution chart, Praxis Precision Medicines ranks #440 out of 741 companies in the Biotechnology industry, placing it in the top 59.4%.
Is Praxis Precision Medicines' Buyback Yield % too high?
Praxis Precision Medicines' current Buyback Yield % is -14.13. Based on the distribution chart, Praxis Precision Medicines ranks #440 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Buyback Yield % compare to IBRX and CORT?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #440 out of 741 companies for Buyback Yield %. This places Praxis Precision Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current Buyback Yield % is -14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.62, compared to a current price of $319.07 — trading 1055.2% above its estimated fair value. The current Buyback Yield % is -14.13. Praxis Precision Medicines' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Buyback Yield % is -14.13 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Praxis Precision Medicines (PRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued.
The current stock price of $319.07 is trading 1055.2% above its estimated GF Value™ of $27.62.
GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.
Key valuation signals for PRAX:
Buyback Yield %: -14.13
GF Value™: $27.62 vs. price of $319.07 (1055.2% above fair value)
No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score
Get the complete analysis for PRAX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRAX has been successfully added to your 
